BioCentury

Inflation Reduction Act

BioCentury In Depth



The Inflation Reduction Act


The Inflation Reduction Act, signed into law on Aug. 16, 2022, set in motion broad-based drug price regulation as well as changes to the Medicare program that are fundamentally reshaping the drug development ecosystem. A comprehensive knowledge of the law has become essential for drug development decision-making, including for investments and pipeline prioritization.


BioCentury is providing deep analysis of the law, exploring its impacts and explaining how the federal government is implementing it. This analysis is complemented by perspectives from business and policy leaders on options for medical product developers to navigate the new landscape, and reporting on the biopharmaceutical industry’s attempts to modify or derail the IRA through litigation and legislation.




Sign up now (free) for access to the featured stories below, and put BioCentury to work for you.



Sign Up
Do you already have an account? Log in.
Inflation Reduction Act Image

Featured Analysis

Complimentary access with registration


More Inflation Reduction Act Coverage from BioCentury

Available to BioCentury Subscribers Only